New Delhi: Remdesvir, the antiviral drug that is in excessive demand amongst COVID-19 sufferers and whose extreme scarcity India is dealing with, just isn’t a positive shot antidote to the illness.
Dr Neeraj Nischal, an extra Professor Internal medicines, AIIMS in an interview with a number one media day by day, defined that Remdesivir is efficient solely on a small group of COVID-19 sufferers.
“Use of Remdesvir for treatment of COVID has very specific indications. It is beneficial only in a very small subset (in terms of shortening the time for recovery by approximately five days) of patients early in the disease and on low-flow oxygen,” stated Dr Nischal to The Times of India.
He additional added, “Outside this group of patients, Remdesivir really is not much better than placebo for COVID.”
Dr Nischal additionally spoke concerning the risks of self-medicating oneself with Remdesivir in opposition to the novel Coronavirus, with out consulting a health care provider.
“Remdesvir is an injectable drug that has to be administered by the intravenous route. The drug itself may cause an allergic reaction, which may be life-threatening in some people. IV cannulation itself can predispose a patient to unnecessary risks of a clot in the veins,” stated Dr Nischal.
He additionally claimed, “It has side effects on the heart and liver, which so far seem to be reversible, but we cannot be sure as the mechanism is not known.”
Addressing the present scarcity of the drug within the nation, Dr Nischal acknowledged, “The decision to use it (Remdesvir) should be based on the clinical status of a patient and not his social status.”
As a parting comment, he stated that Remdesvir could also be efficient when used logically, however not when used indiscriminately.